News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Delphi Genetics Grants Merck & Co., Inc. (MRK) License for the Use of the StabyExpress™ System


10/8/2012 7:21:57 AM

BRUSSELS--(BUSINESS WIRE)--Delphi Genetics SA (“Delphi”) has announced today a broad licensing agreement with a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada, for the use of the StabyExpress™ technology, which allows high yield, cost effective protein expression without the use of antibiotics. Under the agreement, Merck receives a non-exclusive license to use the StabyExpress™ technology for protein expression in research and product development. In exchange, Delphi is eligible to receive milestone payments associated with the development of Merck product candidates that utilize the StabyExpress™ technology, as well as royalties on sales of such products. The financial details of the agreement were not disclosed.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES